PL2667851T3 - Formulacje testosteronu - Google Patents
Formulacje testosteronuInfo
- Publication number
- PL2667851T3 PL2667851T3 PL12700406T PL12700406T PL2667851T3 PL 2667851 T3 PL2667851 T3 PL 2667851T3 PL 12700406 T PL12700406 T PL 12700406T PL 12700406 T PL12700406 T PL 12700406T PL 2667851 T3 PL2667851 T3 PL 2667851T3
- Authority
- PL
- Poland
- Prior art keywords
- testosterone formulations
- testosterone
- formulations
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960003604 testosterone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161436207P | 2011-01-26 | 2011-01-26 | |
| EP11152210 | 2011-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2667851T3 true PL2667851T3 (pl) | 2017-01-31 |
Family
ID=44146428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12700406T PL2667851T3 (pl) | 2011-01-26 | 2012-01-18 | Formulacje testosteronu |
| PL16169138T PL3072505T3 (pl) | 2011-01-26 | 2012-01-18 | Formulacje testosteronu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16169138T PL3072505T3 (pl) | 2011-01-26 | 2012-01-18 | Formulacje testosteronu |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8895053B2 (enExample) |
| EP (2) | EP2667851B1 (enExample) |
| JP (2) | JP6012632B2 (enExample) |
| KR (1) | KR101877476B1 (enExample) |
| CN (1) | CN103327962B (enExample) |
| AR (1) | AR085090A1 (enExample) |
| AU (1) | AU2012210691B2 (enExample) |
| BR (1) | BR112013018951B1 (enExample) |
| CA (1) | CA2824941A1 (enExample) |
| DK (2) | DK2667851T3 (enExample) |
| ES (2) | ES2586122T3 (enExample) |
| HR (2) | HRP20160887T1 (enExample) |
| HU (3) | HUE044327T2 (enExample) |
| IL (1) | IL227454A (enExample) |
| JO (1) | JO3755B1 (enExample) |
| LT (2) | LT3072505T (enExample) |
| MX (1) | MX340259B (enExample) |
| NO (1) | NO2018034I1 (enExample) |
| PL (2) | PL2667851T3 (enExample) |
| PT (2) | PT2667851T (enExample) |
| RS (2) | RS54898B1 (enExample) |
| RU (1) | RU2613891C2 (enExample) |
| SA (1) | SA112330224B1 (enExample) |
| SI (2) | SI3072505T1 (enExample) |
| TR (1) | TR201909271T4 (enExample) |
| TW (1) | TWI564029B (enExample) |
| WO (1) | WO2012101016A1 (enExample) |
| ZA (1) | ZA201305665B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| AU2010243273B2 (en) * | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| HRP20161746T1 (hr) | 2010-10-27 | 2017-02-10 | Ferring B.V. | Postupak za proizvodnju degareliksa i njegovih međuprodukata |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| FI4512390T1 (fi) | 2012-06-01 | 2025-08-01 | Ferring Bv | Degareliksin valmistaminen |
| US8785426B1 (en) * | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
| WO2016205423A2 (en) | 2015-06-15 | 2016-12-22 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| RU2699674C1 (ru) * | 2015-09-30 | 2019-09-09 | Фуджифилм Корпорэйшн | Композиция для чрескожной абсорбции |
| TWI857942B (zh) * | 2017-10-30 | 2024-10-11 | 日商帝國製藥股份有限公司 | 經皮投與製劑 |
| ES2983874T3 (es) | 2018-01-10 | 2024-10-25 | Celista Pharmaceuticals Llc | Pulverización transdérmica de testosterona con película |
| EP3817731B1 (en) | 2018-07-05 | 2025-09-03 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
| US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| CN109700764B (zh) * | 2019-02-20 | 2021-07-06 | 广东食品药品职业学院 | 双氢睾酮原位凝胶喷雾剂及其制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP0002749B2 (en) | 1977-12-26 | 1987-08-12 | IHARA CHEMICAL INDUSTRY Co., Ltd. | Process for producing aromatic monocarboxylic acid |
| ES2052488T3 (es) | 1991-04-25 | 1997-01-01 | Romano Deghenghi | Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante. |
| DK0556034T4 (da) | 1992-02-12 | 2004-11-15 | Daikyo Gomu Seiko Kk | Et medicinsk instrument |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE10107663B4 (de) * | 2001-02-19 | 2004-09-09 | Lts Lohmann Therapie-Systeme Ag | Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| CN1997357A (zh) * | 2003-03-11 | 2007-07-11 | 安塔雷斯制药Ipl股份公司 | 透皮或透粘膜应用活性剂的用途和制剂 |
| US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| ATE534373T1 (de) * | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2007124250A2 (en) * | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| EP1896038B1 (en) * | 2005-06-03 | 2016-11-09 | Acrux DDS Pty Ltd | Method and composition for testosterone transdermal delivery |
| WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
| EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| AU2008231781B2 (en) * | 2007-03-23 | 2012-09-20 | Besins Healthcare Luxembourg Sarl | Compositions and method for treating pediatric hypogonadism |
| IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| EP2257324B1 (en) | 2008-02-11 | 2016-07-27 | Safety Syringes, Inc. | Syringe with safety needle guard and clip to prevent release of guard during reconstitution process |
| AU2010243273B2 (en) | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| WO2012024361A1 (en) * | 2010-08-17 | 2012-02-23 | Biosante Pharmaceuticals, Inc. | Commercial scale production methods for transdermal hormone formulations |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| HRP20161746T1 (hr) | 2010-10-27 | 2017-02-10 | Ferring B.V. | Postupak za proizvodnju degareliksa i njegovih međuprodukata |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| EP3269368A1 (en) | 2011-07-15 | 2018-01-17 | Ferring B.V. | Method for timing a colonoscopy wherein a picosulfate composition is administered |
-
2012
- 2012-01-17 JO JOP/2012/0014A patent/JO3755B1/ar active
- 2012-01-18 CN CN201280006305.2A patent/CN103327962B/zh active Active
- 2012-01-18 DK DK12700406.7T patent/DK2667851T3/en active
- 2012-01-18 EP EP12700406.7A patent/EP2667851B1/en active Active
- 2012-01-18 HR HRP20160887TT patent/HRP20160887T1/hr unknown
- 2012-01-18 PL PL12700406T patent/PL2667851T3/pl unknown
- 2012-01-18 CA CA2824941A patent/CA2824941A1/en not_active Abandoned
- 2012-01-18 PL PL16169138T patent/PL3072505T3/pl unknown
- 2012-01-18 LT LTEP16169138.1T patent/LT3072505T/lt unknown
- 2012-01-18 RS RS20160495A patent/RS54898B1/sr unknown
- 2012-01-18 DK DK16169138.1T patent/DK3072505T3/da active
- 2012-01-18 PT PT127004067T patent/PT2667851T/pt unknown
- 2012-01-18 SI SI201231641T patent/SI3072505T1/sl unknown
- 2012-01-18 US US13/979,881 patent/US8895053B2/en not_active Expired - Fee Related
- 2012-01-18 BR BR112013018951-7A patent/BR112013018951B1/pt active IP Right Grant
- 2012-01-18 TR TR2019/09271T patent/TR201909271T4/tr unknown
- 2012-01-18 RU RU2013133082A patent/RU2613891C2/ru active
- 2012-01-18 WO PCT/EP2012/050695 patent/WO2012101016A1/en not_active Ceased
- 2012-01-18 PT PT16169138T patent/PT3072505T/pt unknown
- 2012-01-18 AU AU2012210691A patent/AU2012210691B2/en active Active
- 2012-01-18 ES ES12700406.7T patent/ES2586122T3/es active Active
- 2012-01-18 SI SI201230575A patent/SI2667851T1/sl unknown
- 2012-01-18 HU HUE16169138 patent/HUE044327T2/hu unknown
- 2012-01-18 HU HUE12700406A patent/HUE027453T4/hu unknown
- 2012-01-18 JP JP2013550826A patent/JP6012632B2/ja not_active Expired - Fee Related
- 2012-01-18 ES ES16169138T patent/ES2741744T3/es active Active
- 2012-01-18 KR KR1020137020996A patent/KR101877476B1/ko not_active Expired - Fee Related
- 2012-01-18 RS RS20190914A patent/RS59012B1/sr unknown
- 2012-01-18 MX MX2013008463A patent/MX340259B/es active IP Right Grant
- 2012-01-18 EP EP16169138.1A patent/EP3072505B1/en active Active
- 2012-01-19 TW TW101102189A patent/TWI564029B/zh not_active IP Right Cessation
- 2012-01-25 SA SA112330224A patent/SA112330224B1/ar unknown
- 2012-01-25 AR ARP120100241A patent/AR085090A1/es not_active Application Discontinuation
-
2013
- 2013-07-11 IL IL227454A patent/IL227454A/en active IP Right Grant
- 2013-07-25 ZA ZA2013/05665A patent/ZA201305665B/en unknown
-
2014
- 2014-10-22 US US14/520,706 patent/US20150110856A1/en not_active Abandoned
-
2016
- 2016-08-09 JP JP2016156246A patent/JP2017019819A/ja not_active Withdrawn
-
2018
- 2018-08-27 HU HUS1800036C patent/HUS1800036I1/hu unknown
- 2018-09-27 NO NO2018034C patent/NO2018034I1/no unknown
- 2018-10-11 LT LTPA2018516C patent/LTPA2018516I1/lt unknown
-
2019
- 2019-07-04 HR HRP20191216TT patent/HRP20191216T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1800036I1 (hu) | Tesztoszteron-készítmények | |
| ZA201509340B (en) | Proliposomal testosterone formulations | |
| GB201111438D0 (en) | Formulation | |
| ZA201309221B (en) | Formulation | |
| ZA201402456B (en) | Formulation | |
| GB201103942D0 (en) | Compositions | |
| GB201110278D0 (en) | Formulations | |
| GB201104849D0 (en) | Compositions | |
| GB201106958D0 (en) | Formulation | |
| GB201102795D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201104284D0 (en) | Formulation | |
| GB201103941D0 (en) | Compositions | |
| GB201103943D0 (en) | Compositions | |
| GB201104200D0 (en) | Compositions | |
| GB201104202D0 (en) | Compositions | |
| GB201103670D0 (en) | Compositions | |
| GB201104948D0 (en) | Compositions |